Psychosis Research Unit, Aarhus University Hospital-Psychiatry, Aarhus, Denmark.
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
J Psychopharmacol. 2022 Nov;36(11):1208-1217. doi: 10.1177/02698811221131992. Epub 2022 Oct 21.
The six-item Positive and Negative Syndrome Scale (PANSS-6) is a measure of the severity of core symptoms of schizophrenia, which can be administered via the brief Simplified Negative and Positive Symptoms Interview (SNAPSI). A recent study has confirmed the validity of PANSS-6 ratings as derived by SNAPSI (PANSS-6) among inpatients with schizophrenia.
We aimed to test the validity of PANSS-6 among outpatients with schizophrenia using PANSS-6 ratings extracted from the 30-item PANSS-30 as derived by the Structured Clinical Interview for the Positive and Negative Syndrome Scale (PANSS-6) as a gold standard reference.
PANSS-6 and PANSS-6 ratings were obtained at two time points by independent raters with established inter-rater reliability. Agreement between PANSS-6 and PANSS-6 ratings was estimated via intra-class coefficients (ICCs) and responsiveness over time was quantified using Spearman's rank correlation coefficients. Post hoc "leave-one-out" analyses were carried out, in which each rater in turn was excluded from the ICC calculations.
Seventy-three outpatients with schizophrenia participated in the study (mean age: 38.3 years; 56% males). The ICC for PANSS-6 versus PANSS-6 was 0.67 [95%CI = 0.56-0.76] and the Spearman's rank correlation coefficient for responsiveness was 0.40 ( = 0.004). When data from a specific outlying rater were excluded, the ICC for PANSS-6 versus PANSS-6 was 0.75 [95% CI = 0.63-0.83] and the Spearman's rank correlation coefficient for responsiveness was 0.55 ( = 0.018).
We found PANSS-6 ratings to have acceptable clinical validity, suggesting that PANSS-6 can be used for both inpatients and outpatients with schizophrenia.
六项目阳性和阴性症状量表(PANSS-6)是一种衡量精神分裂症核心症状严重程度的量表,可以通过简化的阴性和阳性症状访谈(SNAPSI)进行管理。最近的一项研究证实了通过 SNAPSI(PANSS-6)得出的 PANSS-6 评分在住院精神分裂症患者中的有效性。
我们旨在通过使用结构化临床访谈阳性和阴性综合征量表(PANSS-6)作为金标准参考,从 30 项 PANSS-30 中提取 PANSS-6 评分,来测试门诊精神分裂症患者中 PANSS-6 的有效性。
由两位具有既定组内信度的独立评估者在两个时间点获得 PANSS-6 和 PANSS-6 评分。通过组内相关系数(ICC)评估 PANSS-6 与 PANSS-6 评分之间的一致性,并使用 Spearman 等级相关系数来量化随时间的反应性。进行事后“逐一剔除”分析,其中每个评估者依次从 ICC 计算中剔除。
73 名门诊精神分裂症患者参与了研究(平均年龄:38.3 岁;56%为男性)。PANSS-6 与 PANSS-6 之间的 ICC 为 0.67[95%CI=0.56-0.76],反应性的 Spearman 等级相关系数为 0.40(=0.004)。当剔除特定的异常评估者的数据时,PANSS-6 与 PANSS-6 之间的 ICC 为 0.75[95%CI=0.63-0.83],反应性的 Spearman 等级相关系数为 0.55(=0.018)。
我们发现 PANSS-6 评分具有可接受的临床有效性,表明 PANSS-6 可用于住院和门诊精神分裂症患者。